Indeed, blocking estrogen through either use of an estrogen antagonist or estrogen deprivation results in lower AXL mRNA levels in HER2+ ER+ breast cancer cells that have acquired resistance to lapatinib [37]. The gene discussed is ERBB2; the disease is breast cancer.